PANCREATIC CANCER MAY BECOME THE SECOND DEADLIEST CANCER BY 2013. IS THERE A CHANCE TO CHANGE THIS AWFUL PREDICTION?

By 2030, the top cancer killers in the United States will be lung, pancreas and liver, according to a new report published in the American Association for Cancer Research's journal.

Lung cancer is already the top killer overall, but pancreatic and liver cancer will surpass the cancers currently considered the second and third leading causes of death. Right now, second most dangerous is breast cancer for women and prostate cancer for men; and third is colorectal cancer for both men and women.

Researchers looked at trends in cancer incidence and death rates between 2006 and 2010, and used that data -- combined with expected U.S. demographic changes -- to predict numbers for 2030.

The rate of pancreatic cancer has been slowly increasing for the past 15 years. Some of that rise can be attributed to the prevalence of obesity and diabetes.

Many Americans are not aware that the combination of obesity, high-caloric intake and lack of physical activity is the second-leading cause of cancer in the U.S., Indeed, It is linked to at least 12 types of cancer, including pancreatic cancer.  This is an American problem ... If we want to change bad projection of the death rate for pancreatic cancer, it is necessary to increase the investment in education of the population about the importance of changing eating habits and the physical activities to prevent cancer.

You can learn more about how you can prevent the cancer, read my Manual about “Cancer Prevention” 

http://www.amazon.com/Cancer-Prevention-Luis-Mendoza-ebook/dp/B00AXX965Y

Luis Mendoza, MD, PhD

POTENTIAL NEW TARGET IDENTIFIED IN PANCREATIC CANCER

Researchers have identified a potential new method for treating pancreatic cancer, using calcium to overload pancreatic cancer cells and, thus, induce cell death in cancerous cells while sparing healthy cells. 

The key to this discovery, made by Jason Bruce, PhD, from the Physiological Systems and Disease Research Group at the University of Manchester, and colleagues, was identifying the “power source” for calcium pumps in the cancer cells that keep calcium levels low, assisting in cell survival. 

According to background information in the study, maintaining a low concentration of calcium is key to cell survival. Plasma membrane Ca²⁺ ATPase (PMCA) is a protein in the plasma membrane of cells that removes calcium from the cell. PMCA is fueled using adenosine triphosphate (ATP). 

Prior research has shown that many cancer cells, including pancreatic cancer, shift from ATP produced from mitochondria metabolism to a glycolysis ATP. Mitochondria generate approximately 90% of a cells’ energy in normal healthy cells. However, in pancreatic cancer cells it is thought that PMCA may have its own supply of glycolytic ATP, and it is this fuel supply that gives cancer cells a survival advantage over normal cells. 

“Designing drugs to cut off this supply to the calcium pumps might be an effective strategy for selectively killing cancer cells while sparing normal cells within the pancreas,” said Bruce in a prepared statement. 

In order to determine whether pancreatic cells were fuelled by mitochondrial or glycolytic ATP, the researchers used pancreatic tumor cells to test the effect of mitochondrial and glycolytic inhibition on cell death. The results of the study were published in the Journal of Biological Chemistry. 

Mitochondrial inhibition had no effect on cell death compared with control experiments. However, the researchers found that glycolysis inhibition induced ATP depletion, an irreversible increase in calcium, and ultimately cell death. 

“Collectively, the present study suggests that glycolytic ATP synthesis is critically important for maintaining PMCA activity and low resting Ca2+, in human pancreatic ductal adenocarcinoma cell lines,” the researchers wrote. “Furthermore, these findings are translational and provide insights into a potentially new therapeutic avenue for the treatment of pancreatic ductal adenocarcinoma.” 

Source:  cancernetwork.com